CPhI Online

Wuxi Biologics subsidiary agrees 20-year manufacturing deal with global vaccine leader

19 Feb 2020

A subsidiary of WuXi Biologics has signed a 20-year vaccine manufacturing contract worth around USD 3 billion with a global vaccine company, the Chinese contract development and manufacturing organisation (CDMO) said Tuesday.

Under the terms of the deal, Wuxi Vaccines, a joint venture between Wuxi and Shanghai Hile Bio-technology, will build a dedicated vaccine manufacturing facility in Ireland and supply commercial vaccines for the global market.

The integrated plant will include drug substance manufacturing, drug product manufacturing, manufacture science and technology labs and quality control labs and is expected to be operational in 2022.

In November last year, WuXi Vaccines announced USD 240 million investment to build the facility within the WuXi Biologics Campus adjacent to the “Factory of the Future” biologics drug substance manufacturing facility, which is scheduled for commercial manufacturing in 2021.

Dr Chris Chen, CEO of WuXi Biologics and Chairman of WuXi Vaccines said that due to process complexity, extensive analytic testing and rigorous regulatory standards, vaccines are difficult to manufacture.

“This partnership with a global vaccine leader to exclusively manufacture a vaccine for the global market, first of its kind in the industry, is a further testimony to the technical strengths and premier quality demonstrated by WuXi Vaccines,” he added.